A study looking at pazopanib for advanced kidney cancer (Pazo2)

Cancer type:

Kidney cancer
Renal cell cancer
Secondary cancers




Phase 2

This study looked at pazopanib for people with advanced kidney cancer (renal cancer) that hadn’t been treated yet. 

This study was open to people whose cancer had spread to another part of the body and couldn’t have surgery to remove the cancer (advanced cancer). 

This study was open for people to join between 2012 and 2016. These results were reported in 2018. 

Cancer Research UK supported this study.

More about this trial

Pazopanib is a type of targeted cancer drug called a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
Doctors can treat advanced kidney cancer with pazopanib. They usually use it to treat people who have kidney cancer that is not causing them too many symptoms. These are people who are well enough to carry out normal activities, but can’t do heavy physical work (performance status 0 or 1).
In this study, researchers wanted to see if pazopanib worked for people who had symptoms caused by their kidney cancer. These symptoms were affecting their quality of life Open a glossary item and ability to carry on with their daily routine. They had a general health status of performance status 2
The aims of this study were to find out:
  • if pazopanib helped people whose kidney cancer affected their well being and quality of life
  • more about the side effects

Summary of results

The study team suggest pazopanib is acceptable and works well for people with advanced kidney cancer who have a performance status of 2.
About this study
75 people took part in this phase 2 study. Everyone had pazopanib. The doctors could reduce the dose if the side effects became difficult to cope with. 
Everyone had pazopanib until their cancer started to grow again or the side effects became too bad to continue. 
At 6 months of treatment the team wanted to know how many people:
  • didn’t have serious side effects 
  • had stopped treatment for 3 weeks or more due to side effects
  • were alive and had no sign of their kidney cancer
The team found of the 75 people:
  • 46 didn’t have serious side effects
  • 18 had stopped treatment due to side effects
  • 37 were alive and their cancer hadn’t started to grow again    
They also looked at the average length of time people lived without their cancer starting to grow. They found it was 9 months. 
These results suggest for people with a performance status of 2, pazopanib is acceptable and worked well. 
They also suggest that excluding people from clinical trials Open a glossary item based only on their performance status might not be appropriate. 
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal.  The figures we quote above were provided by the research team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Emilio Porfiri

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Birmingham

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

Currently rated: 1.5 out of 5 based on 2 votes
Thank you!
We've recently made some changes to the site, tell us what you think